BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 278 filers reported holding BLUEPRINT MEDICINES CORP in Q4 2020. The put-call ratio across all filers is 4.17 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $136,242 | -17.9% | 2,714 | +3.4% | 0.00% | – |
| Q2 2023 | $165,902 | +48.0% | 2,626 | +5.3% | 0.00% | – |
| Q1 2023 | $112,118 | -23.5% | 2,495 | -26.1% | 0.00% | – |
| Q4 2022 | $146,585 | -37.1% | 3,374 | -4.3% | 0.00% | -100.0% |
| Q3 2022 | $233,000 | +23.9% | 3,527 | -5.0% | 0.00% | – |
| Q2 2022 | $188,000 | -2.6% | 3,712 | +22.8% | 0.00% | – |
| Q1 2022 | $193,000 | -45.5% | 3,024 | -8.3% | 0.00% | -100.0% |
| Q4 2021 | $354,000 | -1.7% | 3,296 | -5.8% | 0.00% | 0.0% |
| Q3 2021 | $360,000 | +18.8% | 3,498 | +0.8% | 0.00% | 0.0% |
| Q2 2021 | $303,000 | +25.2% | 3,471 | +39.8% | 0.00% | 0.0% |
| Q1 2021 | $242,000 | -4.0% | 2,483 | +10.8% | 0.00% | 0.0% |
| Q4 2020 | $252,000 | +30.6% | 2,240 | +7.0% | 0.00% | 0.0% |
| Q3 2020 | $193,000 | +25.3% | 2,094 | +6.1% | 0.00% | 0.0% |
| Q2 2020 | $154,000 | +381.2% | 1,973 | +263.4% | 0.00% | – |
| Q1 2020 | $32,000 | – | 543 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 379,090 | $19,037,900 | 17.25% |
| DAFNA Capital Management LLC | 249,521 | $12,530,945 | 3.90% |
| Rock Springs Capital Management LP | 2,685,294 | $134,855,465 | 3.61% |
| Casdin Capital, LLC | 371,378 | $18,650,603 | 2.06% |
| Novo Holdings A/S | 525,000 | $26,365,500 | 1.95% |
| CHI Advisors LLC | 92,888 | $4,664,835 | 1.85% |
| SECTORAL ASSET MANAGEMENT INC | 165,890 | $8,330,996 | 1.62% |
| Avidity Partners Management LP | 751,600 | $37,745,352 | 1.52% |
| EMERALD ADVISERS, LLC | 607,037 | $30,485,393 | 1.48% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 464,321 | $23,318,201 | 1.41% |